abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapelocationmap-pinminusnewsorganisationotheroverviewpluspreviewprofilerefreshnewssearchsecurityPathtagticktooltiptwitteruniversalityweb

Diese Seite ist auf Deutsch nicht verfügbar und wird angezeigt aufEnglish

Story

Oxfam report says top drug companies focusing on patents, not the poor

In November 2007, Oxfam issued a report, "Investing for life: Meeting  poor people's needs for access to medicines through responsible business practices".  In the report, Oxfam examines the business conduct of 12 pharmaceutical companies with respect to access to medicines for the poor.  The Business & Human Rights Resource Centre invited all 12 companies to respond to the report.  The results to date are below (any future responses received will be added to this page).

On 6 February 2008 Oxfam sent a rejoinder, commenting on the company responses: "Oxfam rejoinder" [DOC]

COMPANY RESPONSES / NON-RESPONSES:

Abbott Laboratories statement [DOC]

AstraZeneca statement [DOC]

Bristol-Myers Squibb did not respond

GlaxoSmithKline statement [DOC]

Eli Lilly declined to respond

Johnson & Johnson statement [DOC]

Merck statement [PDF]

Novartis statement [DOC]

Pfizer statement [DOC]
Pfizer's Malaria Platform [DOC]

Roche declined to respond

Sanofi-Aventis statement [PDF] 

Wyeth did not respond

 

Oxfam Gets A Cold Shoulder From Drugmakers, Pharmalot, 5 Feb 2008 (article commenting on Oxfam's report, the companies' responses, and Oxfam's rejoinder)

Drug makers reject Oxfam targets, in Ethical Corporation, Mar 2008 (scroll down to middle of article)

Unternehmensantworten

Abbott Laboratories Antwort anzeigen
AstraZeneca Antwort anzeigen
Bristol-Myers Squibb

Keine Antwort

Eli Lilly

Keine Antwort

GlaxoSmithKline Antwort anzeigen
Johnson & Johnson Antwort anzeigen
Novartis Antwort anzeigen
Roche

Keine Antwort

Wyeth (part of Pfizer)

Keine Antwort

Story Timeline